Background: Psychosis can be characterized by a disruption in behavior and thought processes, leading to significant distortion in mental capacity and organization of thought. This results in an impaired ability to perceive reality accurately or engage meaningfully with others. In patients with a psychiatric disorder psychotic features including delusions, hallucinations, and disorganized behavior. While traditional antipsychotics tackle positive symptoms, they fall short addressing negative and cognitive aspects, often with adverse effects. About one-third of patients remain unresponsive to current pharmacotherapy. Hence, there's a pressing need to pioneer novel molecules for psychosis treatment. Parkinson Disease is a worldwide neurodegenerative disorder with age being the main possible aspects. The disorder impacts between the ages of 65 and 69 about 0.5–1% of the inhabitants and above the age of 80 it impacts about 1–3% of the population (De Lau andBreteler2006; Toulouse and Sullivan 2008). In PD, in the substantia nigra and pars compacta there is significantly decline in dopaminergic neurons, as a subsequent in striatum reduced level of dopamine. As a result of this there is deficiency of dopamine and abnormalities in their functions. Method: In this study, rotenone was administered in animals at dose of 10 mg/kg for 28 days. Results: The outcome of recent experiment to observe the neurotoxic effects of the administration of rotenone-induced Parkinson's disease (PD) exhibited that administration of rotenone decreased food intake and body weight. It also revealed that locomotor activity and exploratory activity was significantly decreased by the administration of rotenone. The administration of rotenone exhibited impaired motor functions and coordination in Pole test and Inverted screen test. Conclusion: Present study revealed that administration of rotenone for a long term period induced Parkinsonism in rat’s model of PD.